Fibrose pulmonaire idiopathique: nintedanib, pirfénidone, résultats complémentaires des essais cliniques
- 1 September 2015
- journal article
- Published by Elsevier in Revue des Maladies Respiratoires Actualités
- Vol. 7 (3) , 256-262
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2014
- Predicting Pulmonary Fibrosis Disease Course From Past Trends in Pulmonary FunctionChest, 2014
- Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique. Élaborées par le centre national de référence et les centres de compétence pour les maladies pulmonaires rares sous l’égide de la Société de pneumologie de langue françaiseRevue des Maladies Respiratoires, 2013
- A Multidimensional Index and Staging System for Idiopathic Pulmonary FibrosisAnnals of Internal Medicine, 2012
- Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2011
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsThe Lancet, 2011
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Clinical Course and Prediction of Survival in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Herpesvirus DNA Is Consistently Detected in Lungs of Patients with Idiopathic Pulmonary FibrosisJournal of Clinical Microbiology, 2003
- Epstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis.Thorax, 1995